Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Tissue for confirmation can be from primary tumor or recurrence. Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole. Patient has a concurrent malignancy or ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...

Regulatory reviews for ribociclib among patients with early breast cancer are continuously ongoing to include the EMA and China. 1. FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara ...

Whakatāne sisters Nicki Hagen (left) and Rochelle Hollowood were diagnosed with breast cancer two years apart. Photo supplied ...

Ribociclib 200mg; with letrozole 2.5mg; tabs. Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

Stretching PFS in ER-Positive Metastatic Breast Cancer In metastatic breast cancer, the current 14-16 months of PFS with endocrine therapy can be stretched to more than 20 months in the first-line ...